Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Etirinotecan Pegol (NKTR-102) in Patients With Refractory Brain Metastases and Advanced Lung Cancer or Metastatic Breast Cancer (MBC)

NCT02312622 is registered in ClinicalTrials.gov with Joel Neal as lead sponsor.

NCT NCT02312622
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02312622 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Etirinotecan Pegol (NKTR-102) in Patients With Refractory Brain Metastases and Advanced Lung Cancer or Metastatic Breast Cancer (MBC)
Lead sponsor
Joel Neal
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2015
Completion date
July 31, 2019
Enrollment
27 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

extensive-stage small cell lung cancer (sclc), metastatic breast cancer (mbc), recurrent non-small cell lung cancer (nsclc), recurrent small cell lung cancer (sclc), stage iv non-small cell lung cancer (nsclc), tumors metastatic to brain